This compound has the potential as an anticancer agent according to the research published in the journal CHBIOL: Chemistry and Biology this week.
The BLM protein is also known to be important in maintaining stability in cells when they multiply, thus preventing cancer. However, certain types of tumour need BLM to grow. This is typical of osteosarcomas - aggressive malignant tumours often seen in bone cancer – and also soft tissue sarcomas.
Now for the first time scientists have been able to turn off the BLM function in cells using an inhibitor called ML216, which stops cells that express BLM from multiplying, leaving cells without BLM alone.
Tumour treatment one step closer
Professor Ian D. Hickson, who led the research says: “Sarcomas and especially osteosarcomas are notoriously difficult to treat. This compound has the potential to lead to a treatment that could stop such tumours growing.”
Professor Hickson’s team is now working on finding derivatives of the compound that will be more potent and suitable to use as a basis for a drug.
“Once we have the compound in the right form, the next step is to test it using mice as a model and then, all being well, to move on to a clinical trial. However, we are several years off having an actual treatment.” He says.
The Nordea Center for Healthy Ageing was founded at the University of Copenhagen in 2008 thanks to funding from the Nordea Foundation. The centre focuses on interdisciplinary research into how people can live healthy lives and enjoy a robust old age.